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Background: Angiogenesis is essential for tumour growth and metastasis. There are conflicting reports as to whether microvessel
density (MVD) using the endothelial marker CD105 (cluster of differentiation molecule 105) in clear-cell renal cell carcinomas
(ccRCC) is associated with prognosis. Recently, CD105 has been described as a RCC cancer stem cell marker.
Methods: A total of 102 ccRCC were analysed. Representative tumour sections were stained for CD105. Vascularity (endothelial
CD105) was quantified by MVD. The immunohistochemistry analysis detected positive (if present) or negative (if absent) CD105
tumoral staining. This retrospective population-based study was evaluated using Kaplan–Meier method, t-test and Cox
proportional hazard model.
Results: We found that the expression of endothelial CD105 (MVD) negatively correlated with nuclear grade (Po0.001), tumour
stage (Po0.001) and Leibovitch score (Po0.001), whereas the expression of tumoral CD105 positively correlated with these three
clinicopathological factors (Po0.001). In multivariate analysis, tumoral CD105 was found to be an independent predictor of poor
overall survival (P¼ 0.002).
Conclusions: We have shown for the first time that tumoral CD105 is an independent predictive marker for death risk and
unfavourable prognosis in patients with ccRCC after curative resection.
Renal cell carcinomas account for 3% of adult malignancies (Cohen
and McGovern, 2005). They are characterised by resistance to
conventional anticancer therapies, and often diagnosed at metastatic
stages (Flanigan et al, 2004; Cohen and McGovern, 2005).
To date, the assessment of prognosis for RCC patients relies
mainly on clinical parameters such as Fuhrman grades (Fuhrman
et al, 1982) and stages (3, 4). However, these parameters are not
entirely reliable (Minardi et al, 2005). Therefore, identifying better
prognosis factors is needed for more accurate RCC prognosis.
CD105 (cluster of differentiation molecule 105)/endoglin is a
cell transmembrane glycoprotein and a key component of
transforming growth factor-b receptor complex (Gougos and
Letarte, 1990; Derynck and Feng, 1997). It is mainly expressed by
angiogenic endothelial cells and has been correlated with tumour
microvessel density (MVD) (Kumar et al, 1996; Minhajat et al,
2006; Dallas et al, 2008). Consequently, CD105 has been studied as
a potential prognosis factor in RCC with contradictory results
(Sandlund et al, 2006; Dubinski et al, 2012).
Recently, tumoral CD105 has been described as a new RCC
cancer stem cell (CSC) marker (Bussolati et al, 2008). In fact, a
subpopulation expressing membrane CD105 was isolated and it
presented CSC characteristics (clonogenicity, expression of stem
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cell markers and tumour initation capability). Cancer stem cell
markers in solid tumours being associated with tumour progres-
sion (Hermann et al, 2010), we asked whether tumoral CD105
could have a prognosis value in RCC.
Therefore, we evaluated by immunohistochemistry the relation-
ship between CD105 expression in endothelial and tumoral cells
with stages, grades, Leibovitch score (LS) and survival in clear-cell
RCC (ccRCC) patients.
MATERIALS AND METHODS
Patients. Between March 2006 and January 2009, 102 consecutive
cases of partial/radical nephrectomy for ccRCC were enroled in a
retrospective study. They were obtained from Pontchaillou
Hospital (Rennes, France). Informed consent to data and specimen
analysis were obtained from all patients for ethical issues. Each
tumour was graded based on Fuhrman grading system and staged
according to the pTNM 2009 classification system. The follow-up
of patients after nephrectomy consisted of physical examination
and imaging tests every 4–6 months for non-metastatic patients
(M0) and every 2 to 3 months for metastatic patients (M1).
Immunohistochemical staining. Tumour samples were obtained
from formalin-fixed and paraffin-embedded surgical specimens.
After deparaffinisation, rehydration and blocking of endogenous
peroxidase activity, immunohistochemical staining was performed
using a monoclonal mouse anti-human CD105 antibody (Kit
OMniMAP, Abcam, Paris, France; dilution 1 : 100). The immu-
nostaining was performed on the selected paraffin bloc corre-
sponding to the highest Fuhrman grade. The expression of CD105
in tumour cells was recorded as negative (absence of staining) or
positive (presence of staining). Microvessel density (MVD) is the
measurement of the number of vessels per mm2. It was used to
evaluate the expression of CD105 in endothelial cells. It was
recorded in tertiles as low (1; 35–240 vessels per mm2), moderate
(2; 241–815 vessels per mm2) and high (3;X816 vessels per mm2).
In non-tumoral kidney tissue, there was no staining in tubules, but
there was staining in all endothelial cells located in all arteries,
tubule capillaries and glomerular endothelial cells.
Statistical analyses. The correlation between CD105 expression
and tumour stage, grade and LS was evaluated by the non-
parametric Spearman rank test. The t-test was used to assess if
CD105 expression differs significantly between groups.
The LS is a validated histological scoring algorithm in ccRCC for
disease-free survival (DFS) after the nephrectomy in M0. It takes
into account the primary tumour status (pathological T stage), the
regional lymph node status, the tumour size, the nuclear grade and
the presence of histological tumour necrosis. Patients with M0
disease at diagnosis were divided into three risk groups based on
the Leibovitch prognostic score. Risk groups were defined as
low (scores 0–2), intermediate (scores 3–5) and high (X6),
respectively.
Disease-free survival was defined as the time from surgery to the
first documentation of tumour relapse (local relapse or/and distant
metastasis). Overall survival (OS) was defined as the time from
surgery to death or last contact. The DFS and OS were estimated
using Kaplan–Meier method with 95% confidence intervals (CI)
and compared across the groups using the log-rank test.
Based on the CD105 expression in endothelial cells (MVD),
patients were divided into three groups or tertiles: (low (1;
35–240 vessels per mm2), moderate (2; 241–815 vessels per mm2)
and high (3;X816 vessels per mm2)). For each tertile, OS and DFS
were evaluated and compared as described above. In tumour cells,
patients were divided into two groups based on the presence or
absence of CD105 staining. For each group, OS and DFS were
evaluated.
Univariate and multivariate Cox proportional hazard models
were fit to determine the clinical and pathological variables that
were associated with OS and DFS. Analyses were performed
separately for endothelial CD105 (three groups or tertiles) and for
tumoral CD105 (two groups). The variables evaluated for OS were
age, sex, stage (I–III vs IV), endothelial CD105 expression and
tumoral CD105 expression. The variables for DFS were age, sex,
LS, endothelial CD105 expression and tumoral CD105 expression.
The multivariate model was performed using a stepwise selection
approach with type I error of 0.05 for model entry and 0.10 for
elimination. Additional elimination was applied to identify
significant variables at the level of Po0.05. We used PASW
(Predictive Analytics SoftWare) (v 19; IBM SPSS, Armonk,
NY, USA).
RESULTS
Patient characteristics. Patient characteristics are summarised in
Figure 1A. The median age of patients was 62.2 years. Fifteen
patients had metastatic disease (Stage IV) and 87 had non-
metastatic disease (Stage I–III). Forty-two patients had low-nuclear
grade (grades 1 and 2), whereas 60 patients had high-nuclear grade
(grades 3 and 4). Five patients had lymph node metastasis and 45
patients had tumoral histological necrosis. The median tumour size
was 6.2 cm. Twenty-four patients had renal venous invasion. As a
clinical parameter, the ECOG (Eastern cooperative Oncology
Group) Performance Status (PS) was 0 for 70 patients and 1 for 32
patients. None of the patients of this cohort had ECOG PS 41.
Five M0 received adjuvant treatment and M1 patients received an
antiangiogenic therapy as first-line treatment. Median follow-up
was 52 months (4–90 months). In M0 (stages I–III), the median OS
was not reached while it was 29.3 months (95% CI, 0–59.7) in M1
patients (stage IV; Figure 1B). The proportion of patients alive at 5
years was 78% and 39% in M0 and M1, respectively (P¼ 0.001;
Figure 1B). Based on tumour grade, patients were divided into low
grade (G1 and G2) and high grade (G3 and G4). The proportion of
patients alive at 5 years was 90% for low grade compared with 65%
for high grade (P¼ 0.001; Figure 1C). In the M0 population, the
DFS at 5 years for the three Leibovitch risk groups were 96%, 76%
and 42% for low, intermediate and high risk, respectively
(Po0.001) (Data not shown).
Endothelial CD105 expression. Endothelial CD105 expression
was evaluated by immunohistochemistry using MVD measure. As
shown in Figure 2A, tumours were classified into three groups
depending on the number of vessels (endothelial cells) positive for
the CD105 antibody: low (1; 35–240 vessels per mm2; Figure 2A(1)),
moderate (2; 241–815 vessels per mm2; Figure 2A(2)), and high
(3; X816 vessels per mm2) MVD (Figure 2A(3)). The number of
patients in each group was 34, 33 and 35, respectively.
We next analysed the correlation between endothelial CD105
expression (MVD) and tumour stage, nuclear grade and LS. The
median value of MVD was 410 vessels per mm2 (35–1.225). For
tumoral stages, the mean value of MVD was 586 vessels per mm2 in
M0 (stage I–III) and 198 vessels per mm2 in M1 patients (stage IV).
For nuclear grades, the mean value of MVD was 821 for grade 1,
749 for grade 2, 420 for grade 3 and 289 for grade 4. For Leibovitch
risk groups in the M0 cohort, the mean value of MVD was 770, 463
and 350 for low, intermediate and high risk, respectively. In the
entire cohort (M1 and M0), high MVD was significantly correlated
with low-grade ccRCC (rs¼  0.503; Po0.001) and early stages
(pT1 and pT2) (rs¼  0.521; Po0.001; Figure 2B). In the M0
cohort, high MVD was significantly correlated with lower risk
Leibotich score (Po0.001; Figure 2B).
We further analysed patient survival according to MVD. Based
on the three MVD tertiles or groups, the proportion of patients alive
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(OS) at 5 years in the M0 population was 58%, 78%, and 91% for the
first, second, and third tertiles, respectively (P¼ 0.001; Figure 2C).
On the basis of the MVD tertiles, the proportion of patients
alive without disease recurrence (DFS) at 5 years in the M0
population was 56%, 71% and 87% for the first, second and third
tertiles, respectively (P¼ 0.008; Figure 2D).
Tumoral CD105 expression. The expression of CD105 in tumour
cells was recorded by immunohistochemistry as negative
(Figure 3A(1)) or positive (Figure 3A(2), (3) and (4)). Positive
CD105 staining was detected in the cytoplasm of isolated tumour
cells in 29 patients. For each of these cases, the staining was strong
and cytoplasmic. It was observed in a few tumour cells
(Figure 3A(3)) or in clustered tumour cells (Figure 3A(4)).
In the entire cohort (M1 and M0), the presence of tumoral
CD105 staining was directly related to high tumour grade
(rs¼ 0.642; Po0.001) and to the highest tumour stage
(rs¼ 0.505; Po0.001; Figure 3B). Moreover, in the M0 population,
it was found to be directly related to high Leibovich risk group
(rs¼ 0.56; Po0.001; Figure 3B). Four of the five patients with
lymph node metastasis had positive CD105 tumoral staining.
Survival analysis was performed based on positive or negative
CD105 tumoral staining. In the entire cohort (M0 and M1), the OS
at five years was 39% and 84% in positive and negative groups,
respectively (Po0.001). In M0, the median of OS was 60.8 months
in patients with tumoral C105 expression, whereas it was not
reached in patients without expression of tumoral CD105
(P¼ 0.001; Figure 3C).
In M0, the median DFS of positive group (positive CD105
tumoral staining) was 21.5 months, whereas it was not reached in
the negative group (Po0.001; Figure 3D).
Univariate and multivariate analyses. The univariate analysis
highlighted the prognostic value of the tumoral stage for the risk of
death (P¼ 0.001; Tables 1 and 2). However, the tumoral stage had
marginal statistical significance for OS (P¼ 0.075 with endothelial
CD15 and P¼ 0.066 with tumoral CD105) in the multivariate
analysis (Tables 1 and 2). The LS had a prognostic value for
the risk of disease recurrence after nephrectomy in
both univariate (Po0.001) and multivariate analyses (Po0.001
with endothelial CD105 and P¼ 0.002 with tumoral CD105;
Tables 1 and 2).
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Figure 1. Patient characteristics. (A). Patient characteristics (B). Overall survival of stage I–III patients versus stage IV patients (C). Overall survival of
low-grade patients versus high-grade patients.
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To evaluate the importance of endothelial CD105 expression
and tumoral CD105 expression in DFS and OS, univariate analysis
was performed.
Both endothelial and tumoral CD105 were found to be
prognostic factors for OS (Po0.001 for both endothelial and
tumoral CD105) and for DFS (P¼ 0.01 for endothelial CD105 and
Po0.001 for tumoral CD105; Tables 1 and 2).
To examine the independent prognostic significance of these
molecular variables, multivariate analysis was performed. High
expression of endothelial CD105 was revealed as an independent
prognostic factor for increased OS (HR¼ 0.48, 95% CI¼ 0.28–0.85;
P¼ 0.011). In contrast, it was not an independent prognostic factor
for DFS (P¼ 0.224; Table 1).
In the multivariate analysis, the tumoral CD105 expression
increased the risk of death by more than three times (HR¼ 3.76,
95% CI¼ 1.63–8.66; P¼ 0.002), and is associated with shorter DFS
with marginal statistical significance (HR¼ 2.82, 95% CI¼ 0.99–8.05;
P¼ 0.053; Table 2). These results show the independent prognostic
value of tumoral CD105 expression.
DISCUSSION
RCC are characterised by their hypervascularity and their
particular angiogenic microenvironment (Sudarshan et al, 2013).
Therefore, the first-line treatment in metastatic ccRCC is
antiangiogenic therapy, targeting vascular endothelial growth
factor (VEGF) and/or VEGF pathway (Albiges et al, 2011);
(Eisen et al, 2012). RCC are also characterised by unpredictable
prognosis (4). Indeed, clinical parameters such as Fuhrman grade
and stage are not sufficient for prognosis (Volpe and Patard, 2010).
For instance, a low-grade and early-stage tumour can relapse
or/and metastasise after surgery. This emphasises the importance
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Figure 2. Endothelial CD105 expression. (A). Representative examples of (1) low-, (2) moderate- and (3) high-immunohistochemistry expression of
endothelial CD105 on tumoral tissues. (B). Associations of endothelial CD105 expression and tumour characteristics (grade, stage and Leibovitch)
in the entire cohort. (C–D). Kaplan–Meier estimates of 5-year OS (C) and DFS (D) according to endothelial CD105 expression in non-metastatic
patients. ***Po0.001.
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of searching for alternative or complementary indicators directly
related to tumour dissemination within the primary tumours. In
the current study, we focused on CD105 protein expression and its
prognosis value in the most frequent histologic RCC subtype
namely ccRCC.CD105/endoglin is an angiogenic marker (Duff
et al, 2003) and has been recently reported to be a CSC marker in
ccRCC.The expression of CD105 in endothelial cells could signal
future metastasis (Li et al, 2000) but the CD105 expression on
tumour cells in ccRCC has no biological value/significance as yet.
The relationships between the expression of CD105 and the
clinicopathological features of ccRCC are investigated by our
group.
Our data indicate that CD105 expression in endothelial cells
(Vermeulen et al, 1996) was inversely correlated with clinico-
pathological parameters. In fact, MVD scores were significantly
inversely correlated to Fuhrman nuclear grade, tumour stage and
LS. In addition, both disease-free and OS rates of patients with high
endothelial CD105 expression (MVD) were significantly higher
than those for patients with low MVD (first tertile4second
tertile4third tertile). A clear association between high vascularity
and favourable prognosis was found in this patient cohort. In the
multivariate analysis, endothelial CD105 expression retained
independent prognostic significance for OS (HR¼ 0.48, 95%
CI¼ 0.28–0.85; P¼ 0.011). Furthermore, we showed for the first
time, his prognostic significance with the LS. Our results are
consistent with those of previous studies in ccRCC (Sandlund et al,
2006; Yagasaki et al, 2003). It should be noted, however, that an
increased CD105 MVD was reported by others to be associated
with advanced pathological stage and poor clinical outcome in
several types of cancer (Wikstrom et al, 2002; Bochner et al, 1995;
Weidner et al, 1991). This inverse relationship in ccRCC could be
due to MVD correlation with tumour fibrosis and the development
of large-diameter vessels in ccRCC (Delahunt et al, 1997).
The tumoral stage is known to be an independent prognostic
factor. In our study, we found a significant statistical difference
between tumoral stages (M0 vs M1) and the OS (P¼ 0.001) in the
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Figure 3. Tumoral CD105 expression. (A). Immunohistochemical images of four cases with tumours denoted as having (2-3-4) tumoral CD105 or
not (1). (B). Correlations between the presence of tumoral CD105 by immunochemistry and tumor characteristics (grade, stage and Leibovitch) in
the entire cohort. (C–D). Kaplan–Meier estimates of 5-year OS (C) and DFS (D) according to the presence or the absence of tumoral CD105 in
non-metastatic patients. ***Po0.001.
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univariate analysis but not reproduced in the multivariate analysis
(P¼ 0.066). That is likely due to overfit of the model, because of
the low numbers and events. Larger cases or prolonged follow up
are still needed. In our cohort, we confirmed the prognostic value
of the LS in predicting the DFS in M0 both in univariate
(Po0.001) and multivariate analyses (Po0.001 with endothelial
CD105 and P¼ 0.002 with tumoral CD105).
Several cancers are now considered to contain small subsets of
stem-like cells called tumour-initiating or cancer stem cells. These
cells acquire greater capacity for self-renewal, differentiation,
antiapoptotic features and anchorage independence and thus can
migrate to distant sites to initiate new tumour formation. At present,
there is an increasing evidence that cancer stem cells are associated
with posttreatment relapse. CD105 has been reported to be a stem
cell marker in ccRCC (Bussolati et al, 2008; Grange et al, 2011).
The relationships between the expression of CD105 in tumoral
cells and the clinicopathological features of ccRCC are investigated
for the first time by our group.
Positive expression of CD105 in tumoral cells was found to be
significantly and directly correlated to high-grade tumours, more
advanced tumour stages and high LS. In addition, both disease-free
and OS rates of patients with positive tumoral CD105 expression
were significantly lower (Po0.001) than for patients with negative
tumoral CD105 expression.
In the multivariate analysis, tumoral CD105 expression retained
the poor prognostic significance for OS (HR¼ 3.76, 95%
CI¼ 1.63–8.66; P¼ 0.002) and was associated with shorter DFS
with marginal statistical significance (HR¼ 2.82, 95% CI¼
0.99–8.05; P¼ 0.053). Thus, tumoral CD105 immunoexpression
in paraffin-embedded tissue seems to be useful in stratifying
ccRCC patients into two prognostic groups. High mortality and
increased invasiveness have been shown in patients expressing
tumoral CD105 (DFS median of 21.5 months and OS median of
60.8 months in M0), indicating the possibility of an early tumour
cell dissemination. Regarding our results, it seems that high-vessel
count alone is not sufficient for tumour cell dissemination
evaluation. Tumoral CD105 gives important additional informa-
tion of the tumour aggressiveness, improving the ability to identify
relevant risk groups for relapse and development of metastasis in
ccRCC.
This may improve the future possibility for specific treatment of
ccRCC. Several studies using mice models have shown that selected
Table 1. Evaluation of prognostic role of endothelial CD105 on OS and DFS in univariate and multivariate analyses
Crude estimates Adjusted estimates
HR (95% CI) P-value HR (95% CI) P-value
OS in all cohort (Patients n¼102)
Age 1.01 0.98–1.04 0.71
Sex (M/F) 1.72 0.70–4.24 0.24
Stage (M1/M0) 3.81 1.71–8.45 0.001 2.19 0.92–5.20 0.075
CD105 tertiles (3rd/2nd/1st) 0.41 0.25–0.69 o0.001 0.48 0.28–0.85 0.011*
DFS (Patients n¼87)
Age 1.02 0.98–1.05 0.44
Sex (M/F) 2.73 0.79–9.46 0.11
Leibovich risk groups (Low/intermediate/high) 4.23 2.19–8.17 o0.001 3.84 1.93–7.62 o0.001*
CD105 Tertiles (3rd/2nd/1st) 0.46 0.25–0.83 0.010 0.65 0.33–1.30 0.224
Abbreviations: CD105¼ cluster of differentiation molecule 105; CI¼ confidence interval; DFS¼disease-free survival; F¼ female; HR¼hazard ratio; M¼male; M0¼ non-metastatic group;
M1¼metastatic group; OS¼overall survival
*Po0.05 (statistically significant difference).
Table 2. Evaluation of prognostic role of tumoral CD105 on OS and DFS in univariate and multivariate analyses
Crude estimates Adjusted estimates
HR (95% CI) P-value HR (95% CI) P-value
OS in all cohort (Patients n¼102)
Age 1.01 0.98–1.04 0.71
Sex (M/F) 1.72 0.70–4.24 0.24
Stage (M1/M0) 3.81 1.71–8.45 0.001 2.27 0.95–5.42 0.066
Tumoral CD105 (Positive/negative) 4.82 2.23–4.82 o0.001 3.76 1.63–8.66 0.002*
DFS (Patients n¼87)
Age 1.02 0.98–1.05 0.44
Sex (M/F) 2.73 0.79–9.46 0.11
Leibovich risk groups (Low/intermediate/high) 4.23 2.19–8.17 o0.001 3.21 1.54–6.66 0.002*
Tumoral CD105 (Positive/negative) 7.37 2.88–18.9 o0.001 2.82 0.99–8.05 0.053
Abbreviations: CD105¼ cluster of differentiation molecule 105; CI¼ confidence interval; DFS¼disease-free survival; F¼ female; HR¼hazard ratio; M¼male; M0¼ non-metastatic group;
M1¼metastatic group; OS¼overall survival.
*Po0.05 (statistically significant difference).
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anti-CD105 mAb are effective in reducing or suppressing
angiogenesis, tumour growth and metastasis (Seon et al, 1997;
Takahashi et al, 2001). TRC105, an anti-CD105 mAb, is a novel
targeted therapy used in phase-I study in patients with advanced
refractory solid tumours. Phase-I clinical studies are currently
tested to evaluate TRC105 efficiency in a wide variety of cancer
types (Rosen et al, 2012).
In summary, the expression of CD105 in tumoral cells is an
independent predictor of death risk and unfavourable prognosis in
patients with clear cell RCC. Tumoral CD105 was a predictor of
patient’s outcomes than other clinicopathological factors. Thus, the
ability to qualitatively distinguish between endothelial CD105 and
tumoral CD105 may be important in the assessment of tumour
prognosis. As a nonsurgical strategy, therapy targeting CD105 cancer
stem cells may represent a treatment strategy for clear cell RCC.
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